Repligen (NASDAQ:RGEN) Shares Down 10.3% – Time to Sell?

Repligen Corporation (NASDAQ:RGEN) shares fell 10.3% during mid-day trading on Thursday . The stock traded as low as $111.40 and last traded at $111.5560. 189,490 shares traded hands during trading, a decline of 77% from the average session volume of 820,074 shares. The stock had previously closed at $124.40.

Analysts Set New Price Targets

Several brokerages recently issued reports on RGEN. Barclays reduced their price objective on Repligen from $175.00 to $145.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 14th. Wall Street Zen cut Repligen from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. UBS Group reduced their price objective on Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Canaccord Genuity Group cut their target price on Repligen from $165.00 to $145.00 and set a “hold” rating on the stock in a research note on Monday. Finally, HC Wainwright raised their target price on Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, March 23rd. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $170.93.

Repligen Price Performance

The company has a quick ratio of 7.12, a current ratio of 8.37 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $6.63 billion, a P/E ratio of 138.35, a PEG ratio of 2.22 and a beta of 1.19. The business has a 50 day simple moving average of $123.16 and a 200-day simple moving average of $145.59.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The company had revenue of $197.91 million for the quarter, compared to analysts’ expectations of $192.23 million. Repligen had a return on equity of 4.71% and a net margin of 6.62%.The firm’s quarterly revenue was up 18.1% compared to the same quarter last year. During the same period last year, the business posted $0.44 earnings per share. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Analysts predict that Repligen Corporation will post 1.97 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Bayforest Capital Ltd acquired a new position in shares of Repligen during the fourth quarter valued at $32,000. Rachor Investment Advisory Services LLC acquired a new position in shares of Repligen during the fourth quarter valued at $33,000. Measured Wealth Private Client Group LLC acquired a new position in shares of Repligen during the third quarter valued at $29,000. Los Angeles Capital Management LLC acquired a new position in shares of Repligen during the fourth quarter valued at $36,000. Finally, Farther Finance Advisors LLC increased its holdings in shares of Repligen by 61.8% during the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 128 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.